Innoviva (INVA) closed at $18.86 on November 11, 2026, down 1.2% from the previous close, on volume of 604,280 shares (30-day average 800,622).
Data as of November 11, 2026.
Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress
Business Wire (Wed, 4-Nov 4:05 PM ET)
Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
Business Wire (Mon, 19-Oct 8:00 AM ET)
Innoviva to Participate in Upcoming Investor Conferences
Business Wire (Wed, 2-Sep 8:00 AM ET)
Innoviva’s Zoliflodacin Phase 3 Results Signal a Turning Point in Gonorrhea Treatment
Market Chameleon (Fri, 12-Dec 2:31 AM ET)
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
Innoviva trades on the NASDAQ stock market under the symbol INVA.
As of November 12, 2026, INVA stock price climbed to $19.03 with 204,935 million shares trading.
INVA has a beta of 0.04, meaning it tends to be less sensitive to market movements. INVA has a correlation of 0.00 to the broad based SPY ETF.
INVA has a market cap of $1.35 billion. This is considered a Small Cap stock.
Last quarter Innoviva reported $106 million in Revenue and -$1.03 earnings per share. This fell short of revenue expectation by $-9 million and missed earnings estimates by -$1.40.
In the last 3 years, INVA traded as high as $25.15 and as low as $13.39.
The top ETF exchange traded funds that INVA belongs to (by Net Assets): IJR, VTI, IWM, VB, DFSV.
INVA has underperformed the market in the last year with a price return of -13.1% while the SPY ETF gained +12.4%. INVA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -8.3% and -9.9%, respectively, while the SPY returned -1.1% and -1.6%, respectively.
INVA support price is $18.48 and resistance is $19.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INVA shares will trade within this expected range on the day.
